ArticleInfection2026
Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnterococcal bacteraemia is associated with high mortality rates ranging from 14% to 50% and is one of the most common causes of infective endocarditis. The DENOVA score is a validated screening tool for patients with monomicrobial E. faecalis bacteraemia who require echocardiography to rule out infective endocarditis.
methodsAdult patients hospitalized at Hannover Medical School during the years of 2021 and 2022 with at least one paired blood culture positive for Enterococcus species were included in this retrospective observational study. Risk factors associated with in-hospital mortality were identified through a multivariable analysis using logistic regression. Clinical differences associated with the underlying pathogen were analysed. The performance of the DENOVA score for predicting infective endocarditis in enterococcal bacteraemia was evaluated in a high-risk cohort outside its validated application for monomicrobial E. faecalis bacteraemia.
resultsA total of 271 cases of enterococcal bacteraemia were included (65.7% E. faecium, 31.4% E. faecalis, 3% other enterococci). Patients with E. faecium bacteraemia had more vancomycin-resistant cases, longer hospital stays and a higher in-hospital mortality rate in comparison to E. faecalis bacteraemia. The Charlson Comorbidity Index, the Pitt Bacteraemia Score, and E. faecium bacteraemia were all factors independently associated with in-hospital mortality. 5% of enterococcal bacteraemia resulted in infective endocarditis (10.6% E. faecalis vs. 3.4% E. faecium). Applying the DENOVA score in our cohort let to a sensitivity of 86.7% and a specificity of 67.5% for predicting infective endocarditis.
conclusionEnterococcal bacteraemia remains a clinical challenge with high morbidity and mortality. Our results suggest that the application of the DENOVA score might be possible in a high-risk cohort and even beyond its original validation. Future research should focus on personalized risk stratification and tailored management strategies to improve patient outcomes.
Indexed as
Identifiers
42307837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.